CA1263119A - Production of 2-(2- pyridylmethylsulfinyl)benzimidazole compounds - Google Patents
Production of 2-(2- pyridylmethylsulfinyl)benzimidazole compoundsInfo
- Publication number
- CA1263119A CA1263119A CA000573673A CA573673A CA1263119A CA 1263119 A CA1263119 A CA 1263119A CA 000573673 A CA000573673 A CA 000573673A CA 573673 A CA573673 A CA 573673A CA 1263119 A CA1263119 A CA 1263119A
- Authority
- CA
- Canada
- Prior art keywords
- vanadium
- alkyl
- compound
- alkoxy
- fluorinated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 14
- HBDKFZNDMVLSHM-UHFFFAOYSA-N 2-(pyridin-2-ylmethylsulfinyl)-1h-benzimidazole Chemical class N=1C2=CC=CC=C2NC=1S(=O)CC1=CC=CC=N1 HBDKFZNDMVLSHM-UHFFFAOYSA-N 0.000 title abstract description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims abstract description 38
- 150000003682 vanadium compounds Chemical class 0.000 claims abstract description 13
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 9
- 230000003647 oxidation Effects 0.000 claims abstract description 8
- -1 cyano, carboxy Chemical group 0.000 claims description 31
- 125000000217 alkyl group Chemical group 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 17
- 125000003545 alkoxy group Chemical group 0.000 claims description 16
- XHCLAFWTIXFWPH-UHFFFAOYSA-N [O-2].[O-2].[O-2].[O-2].[O-2].[V+5].[V+5] Chemical compound [O-2].[O-2].[O-2].[O-2].[O-2].[V+5].[V+5] XHCLAFWTIXFWPH-UHFFFAOYSA-N 0.000 claims description 8
- CMZUMMUJMWNLFH-UHFFFAOYSA-N sodium metavanadate Chemical compound [Na+].[O-][V](=O)=O CMZUMMUJMWNLFH-UHFFFAOYSA-N 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- MFWFDRBPQDXFRC-LNTINUHCSA-N (z)-4-hydroxypent-3-en-2-one;vanadium Chemical compound [V].C\C(O)=C\C(C)=O.C\C(O)=C\C(C)=O.C\C(O)=C\C(C)=O MFWFDRBPQDXFRC-LNTINUHCSA-N 0.000 claims description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- UNTBPXHCXVWYOI-UHFFFAOYSA-O azanium;oxido(dioxo)vanadium Chemical compound [NH4+].[O-][V](=O)=O UNTBPXHCXVWYOI-UHFFFAOYSA-O 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- 125000004423 acyloxy group Chemical group 0.000 claims description 3
- 125000004414 alkyl thio group Chemical group 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 125000004104 aryloxy group Chemical group 0.000 claims description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 125000005079 alkoxycarbonylmethyl group Chemical group 0.000 claims description 2
- 150000008282 halocarbons Chemical class 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 150000002431 hydrogen Chemical group 0.000 claims 2
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims 1
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims 1
- 239000005456 alcohol based solvent Substances 0.000 claims 1
- 239000004210 ether based solvent Substances 0.000 claims 1
- 239000005453 ketone based solvent Substances 0.000 claims 1
- 150000002825 nitriles Chemical class 0.000 claims 1
- PLITYYGQMDTHMM-UHFFFAOYSA-N 2-(pyridin-2-ylmethylsulfanyl)-1h-benzimidazole Chemical class N=1C2=CC=CC=C2NC=1SCC1=CC=CC=N1 PLITYYGQMDTHMM-UHFFFAOYSA-N 0.000 abstract description 5
- 239000006227 byproduct Substances 0.000 abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- 239000013078 crystal Substances 0.000 description 25
- 125000004432 carbon atom Chemical group C* 0.000 description 17
- 229960002163 hydrogen peroxide Drugs 0.000 description 14
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 13
- 238000001914 filtration Methods 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 7
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000002425 crystallisation Methods 0.000 description 6
- 230000008025 crystallization Effects 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 5
- 125000002252 acyl group Chemical group 0.000 description 5
- 150000004682 monohydrates Chemical class 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 4
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 4
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 3
- 235000019345 sodium thiosulphate Nutrition 0.000 description 3
- 150000003462 sulfoxides Chemical class 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 125000005115 alkyl carbamoyl group Chemical group 0.000 description 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 150000003568 thioethers Chemical class 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- IRSPCJLMPFDMGD-UHFFFAOYSA-N 1-hydroxybenzimidazole Chemical compound C1=CC=C2N(O)C=NC2=C1 IRSPCJLMPFDMGD-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 101100379067 Caenorhabditis elegans anc-1 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 101000654316 Centruroides limpidus Beta-toxin Cll2 Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 229910019501 NaVO3 Inorganic materials 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical class [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- KFQJZAUSIGVUOP-UHFFFAOYSA-N [O-][n+]1c([nH]c2ccccc12)S(=O)(=O)Cc1ccccn1 Chemical class [O-][n+]1c([nH]c2ccccc12)S(=O)(=O)Cc1ccccn1 KFQJZAUSIGVUOP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000005242 carbamoyl alkyl group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 125000005117 dialkylcarbamoyl group Chemical group 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229940052308 general anesthetics halogenated hydrocarbons Drugs 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001145 hydrido group Chemical group *[H] 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- JYJVVHFRSFVEJM-UHFFFAOYSA-N iodosobenzene Chemical compound O=IC1=CC=CC=C1 JYJVVHFRSFVEJM-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- QMYTXCUSWCFXLY-UHFFFAOYSA-N methanol;triethylazanium;hydroxide Chemical compound [OH-].OC.CC[NH+](CC)CC QMYTXCUSWCFXLY-UHFFFAOYSA-N 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000005186 naphthyloxy group Chemical group C1(=CC=CC2=CC=CC=C12)O* 0.000 description 1
- 125000005447 octyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- IXZDIALLLMRYOU-UHFFFAOYSA-N tert-butyl hypochlorite Chemical compound CC(C)(C)OCl IXZDIALLLMRYOU-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 150000003681 vanadium Chemical class 0.000 description 1
- 229910001935 vanadium oxide Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Abstract of the disclosure 2-(2-pyridylmethylsulfinyl)benzimidazole compounds are produced by subjecting 2-(2-pyridylmethylthio)benz-imidazole compounds to oxidation with hydrogen peroxide in the presence of vanadium compounds in good yield and with low production of by-products.
Description
3LZ6~
1 Produc-tion of 2-(2-pyridylmethylsulElnyl)benzimidazole .
Compounds -This invention relates to ~he production of 2-(2-pyridylmethylsulEinyl)benzimidazole compounds (refer to, for example, U.S. Patent No.4255~31, European Patent Laid-Open No.45200, No.74341, No.80602, Mo.5129, No.174726, No.175464, sritish Patent Laid-Open No.2134523A), which are useful as antiulcer agents.
~s a method for production of 2-(2-pyridyl-methylsulfinyl)benzimidazole compounds, an oxida-tion o~ the corresponding 2-(2-pyridylmethyl-thio)benz-imidazole compounds with m-chloroperbenzoic acid is mentioned (r~ r to, for example, U.S. Patent No.4255431, European Patent Laid-Open No~0602).
Generally known methods for production of sulfoxides from sulfides include oxidation with peracid, hydrogen peroxide, iodosobenzene, N-halosuccinimide, tertiary butyl hypochloride, sodium metaperiodate, selenium dioxide, bromine, chlorine, or ozone [Refer -to: Saul Patai, The chemistry of ethers, crown ethers, hydroxyl groups and their sulphur analogues, Supplement E, Part 1, p.539-608, John Wllley & Sons, An In-terseience Publication (1980), Miehel Madeselaire, Tetrahedron ~eport Number 210, "Syn-thesis of Sulfoxides by Oxidation of Thioethers", Tetra-hedron, 42, 5459-5~95 (1986)].
~ lowever, the speeifications or referenees do not inelude eoncrete examples of prac-tieal production of 2-(2-pyridylmethylsulfinyl)benzimida-zole eompounds by o~idation with hydrogen peroxide as theoxidizin~ a~ent.
Oxidat:lon of 2-(2-pyridylmethylthio)benzimidazole eompounds with m-ehloroperbenzole aeid gives 2-(2-pyridyl-me~h-ylsulfinyl)benzimldazole eompounds only in low yields, producing much side products such as 2-(2~pyridylmethyl-1 sul~onyl)benzimidazole N-oxide. Such side products are very difficult to remove from 2-(2-pyridylmethylsul-finyl)benzimidazole compounds with usual methods of puri-fication, such as recrystallization. Expensiveness of m chloroperbenzoic acid is an additional problem.
There are some problems in oxidation of 2-(2-pyridyl-methylthio)benzimidazole compounds with one of the oxi-, dizing agents described above other than hydrogen per-oxide; the reaction will not proceed in many cases, and the yield is very low (less than about 75~) because of degradation or production of a great ammount of hy-products.
As the resul-ts of the inventors' researches to find a method for production of 2-(2-pyridylmethylsulfinyl)benz-imidazole compounds from 2-(2-pyridylmethyl-thio)benzimida-zole compounds in good yield and with low production of by-products such as 2-(2-pyridylmethylsulfonyl)benz-imidazole N-oxides, -the inventors have found -that oxidation wi-th hydrogen peroxide in the presence of vanadium com-pounds, for example,vanadium oxides or vanadium salts. asthe catalyst accomplishes the purpose, and have comPleted the in~ention after further researches.
This invention relates to a method for producing ~ compound having the formula (II):
~ R~
wherein the ring A may be substituted; R1 is a hydrogen atom or an N-protective group; R2, R3 an~ R~ are independently hydrogen atom, an alkyl group which may be Eluorinated or an alkoxy group which may ~e fluorinated, which comprise~ subjecting a compound having the Eormula (I):
i3.
l~vrN~--S_Cll~
wher~in ~, R1, R2, R3 and R4 are the same as described above, to oxidation with hydrogen peroxide in -the presence of vanadium compounds.
In compounds (I) and (II~, -the substituents in the ring A include alkyl, halogen, cyano, carboxy, carboalkoxy, carboalkoxyalkyl, carbamoyl, carbamoylalkyl, hydroxy, alkoxy, hydroxyalkyl, trifluoromethyl, acyl, carbamoyloxy, nitro, acyloxy, aryl, aryloxy, alkylthio and alkylsulfi-nyl etc. The alkyl groups are desirably those having to 7 carbon atoms, including methyl, ethyl, propyl, iso-propyl, butyl, isobutyl, pentyl, hexyl and heptyl e-tc.
The halogen atoms include fluorine, chlorine and bromine atoms, among which the fluorine atom is the most desirable.
The carboalkoxy groups are desirably those in which the alkoxy group has l to 4 carbon atoms, including carbo-methoxy (CH300C-) and carboethoxy (C2H500C-) etc. The carboalkoxyalkyl groups are desirably those in which the alkoxy and alkyl groups have 1 to 4 carbon atoms each, including carbomethoxymethyl (CH300CCH2-), carbomethoxy-ethyl (CH300CC2H4-), carboethoxyllle-thyl (C2ll500CCH2-) and carboethoxyethyl (C2H500CC2H4 ~ etc. The carbamoyla~kyl groups are desirably thosè in which the alkyl group has 1 to 4 carbon atoms, including carbamoylmethyl (~l2NCOCH2-) and carbamoylethyl (H2NCOC2H~-) e-tc. The alkoxy groups are desirably those haviny 1 to 5 carbon atoms, including methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy anc1 pentoxy etc. The hydroxyalkyl groups are desirably those.in which ~le alk~l ~roup has 1 to 7 carbon atoms, inclu-diny hydroxymethyl and 1-hydroxy-propyl-2,1-hydroxy-ethyl-2,1-hydroxy-2-metl1yl-propyl-2 e-tc. The acyl 1 groups are desirably those having 1 to ~ carbon atoms, including formyl, acetyl, propionyl, butylyl an~ isobuty-lyl etc. T~le acyloxy groups are desirably those in which the acyl group has 1 to 4 carbon atoms, including ~or-myloxy, acetyloxy, propionyloxy, butylyloxy, and iso-butylyloxy etc. The aryl groups include phenyl, tolyl and naphthyl etc. The aryloxy groups include phenyloxy, tolyloxy and naphthyloxy etc. The alkylthio groups are desirably those in which the aLkyl group has 1 to 4 carbon atoms, including methylthio, ethylt}lio and propylthio etc The alkylsulfinyl groups are desirably those having l to 6 carbon atoms, including methylsulfinyl, ethylsulfi-nyl and propylsulfinyl e-tc.
The ring A is not substituted or is substituted at the 4- or 5-position particularly desirably with alkyl, halogen, trifluoromethyl or alkoxy among the substituents described above.
The N-protective groups represen-ted by R1 include alkyl, acyl, carboalkoxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, alkylcarbonylmethyl, alkoxycarbonyl-me-thyl and alkylsulfonyl etc. The alkyl groups are desirably those having 1 to 5 carbon atoms, including methyl, ethyl, propyl, isopropyl, butyl, isobutyl and pentyl etc. The acyl groups include the same ~roups as those described ~or the substituents o~ the ring ~. The carboalko~y groups include the same groups as those described for the substituents of the ring A. The alkylcarbamoyl groups are represented by the Eormula:
}~
alkyl wherein the alkyl group has desirably 1 to ~ carbon atoms, includlng me-thylcarbamoyl, ethylcarbamoyl, propylcarba-moyl and isopropylcarbamoyl e~c. The dialykylcarbamoyl 5 groups are r~presented by the formula:
allcyl\
alkyi/
.. . .. .
~L~
1 wherein the ~lkyl groups have desirably 1 to 4 carbon ~toms each, includin~ dimethylcarbamoyl, dietllylcarbamoyl and N-methyl-N-ethylcarbamoyl e-tc. The alkylcarbonyl-methyl groups are represented by the Eormula: alkyl-CO-C1~2- wherein the alkyl group has desirably 1 to 4 carbon atoms, including acetylmethyl and propionylmethl etc.The alkoxycarbonylmethyl groups are represen-ted by the formula: alkyl-OCO-CH2- wherein the alkyl group h~s desir-ably 1 to 4 carbon atoms, including methoxycarbonylmethyl, ethoxycarbonylmethyl and propoxycarbonylmethyl etc. The alkylsulfonyl groups are represented by -the formula:
alkyl-SO2- wherein the alkyl group has desirably 1 to 4 carbon atoms, including methylsulfonyl, ethylsulfonyl, propylsulfonyl and isopropylsulfonyl etc.
The alkyl groups which may be fluorinate~ repre-sented by R2, R3 and R4, have desirably 1 to 4 carbon atoms each. Such unsubsti.tuted alkyl groups include methyl, ethyl, propyl, isopropyl, butyl and isobutyl etc.
Such Eluorinated alkyl groups include trifluoromethyl,
1 Produc-tion of 2-(2-pyridylmethylsulElnyl)benzimidazole .
Compounds -This invention relates to ~he production of 2-(2-pyridylmethylsulEinyl)benzimidazole compounds (refer to, for example, U.S. Patent No.4255~31, European Patent Laid-Open No.45200, No.74341, No.80602, Mo.5129, No.174726, No.175464, sritish Patent Laid-Open No.2134523A), which are useful as antiulcer agents.
~s a method for production of 2-(2-pyridyl-methylsulfinyl)benzimidazole compounds, an oxida-tion o~ the corresponding 2-(2-pyridylmethyl-thio)benz-imidazole compounds with m-chloroperbenzoic acid is mentioned (r~ r to, for example, U.S. Patent No.4255431, European Patent Laid-Open No~0602).
Generally known methods for production of sulfoxides from sulfides include oxidation with peracid, hydrogen peroxide, iodosobenzene, N-halosuccinimide, tertiary butyl hypochloride, sodium metaperiodate, selenium dioxide, bromine, chlorine, or ozone [Refer -to: Saul Patai, The chemistry of ethers, crown ethers, hydroxyl groups and their sulphur analogues, Supplement E, Part 1, p.539-608, John Wllley & Sons, An In-terseience Publication (1980), Miehel Madeselaire, Tetrahedron ~eport Number 210, "Syn-thesis of Sulfoxides by Oxidation of Thioethers", Tetra-hedron, 42, 5459-5~95 (1986)].
~ lowever, the speeifications or referenees do not inelude eoncrete examples of prac-tieal production of 2-(2-pyridylmethylsulfinyl)benzimida-zole eompounds by o~idation with hydrogen peroxide as theoxidizin~ a~ent.
Oxidat:lon of 2-(2-pyridylmethylthio)benzimidazole eompounds with m-ehloroperbenzole aeid gives 2-(2-pyridyl-me~h-ylsulfinyl)benzimldazole eompounds only in low yields, producing much side products such as 2-(2~pyridylmethyl-1 sul~onyl)benzimidazole N-oxide. Such side products are very difficult to remove from 2-(2-pyridylmethylsul-finyl)benzimidazole compounds with usual methods of puri-fication, such as recrystallization. Expensiveness of m chloroperbenzoic acid is an additional problem.
There are some problems in oxidation of 2-(2-pyridyl-methylthio)benzimidazole compounds with one of the oxi-, dizing agents described above other than hydrogen per-oxide; the reaction will not proceed in many cases, and the yield is very low (less than about 75~) because of degradation or production of a great ammount of hy-products.
As the resul-ts of the inventors' researches to find a method for production of 2-(2-pyridylmethylsulfinyl)benz-imidazole compounds from 2-(2-pyridylmethyl-thio)benzimida-zole compounds in good yield and with low production of by-products such as 2-(2-pyridylmethylsulfonyl)benz-imidazole N-oxides, -the inventors have found -that oxidation wi-th hydrogen peroxide in the presence of vanadium com-pounds, for example,vanadium oxides or vanadium salts. asthe catalyst accomplishes the purpose, and have comPleted the in~ention after further researches.
This invention relates to a method for producing ~ compound having the formula (II):
~ R~
wherein the ring A may be substituted; R1 is a hydrogen atom or an N-protective group; R2, R3 an~ R~ are independently hydrogen atom, an alkyl group which may be Eluorinated or an alkoxy group which may ~e fluorinated, which comprise~ subjecting a compound having the Eormula (I):
i3.
l~vrN~--S_Cll~
wher~in ~, R1, R2, R3 and R4 are the same as described above, to oxidation with hydrogen peroxide in -the presence of vanadium compounds.
In compounds (I) and (II~, -the substituents in the ring A include alkyl, halogen, cyano, carboxy, carboalkoxy, carboalkoxyalkyl, carbamoyl, carbamoylalkyl, hydroxy, alkoxy, hydroxyalkyl, trifluoromethyl, acyl, carbamoyloxy, nitro, acyloxy, aryl, aryloxy, alkylthio and alkylsulfi-nyl etc. The alkyl groups are desirably those having to 7 carbon atoms, including methyl, ethyl, propyl, iso-propyl, butyl, isobutyl, pentyl, hexyl and heptyl e-tc.
The halogen atoms include fluorine, chlorine and bromine atoms, among which the fluorine atom is the most desirable.
The carboalkoxy groups are desirably those in which the alkoxy group has l to 4 carbon atoms, including carbo-methoxy (CH300C-) and carboethoxy (C2H500C-) etc. The carboalkoxyalkyl groups are desirably those in which the alkoxy and alkyl groups have 1 to 4 carbon atoms each, including carbomethoxymethyl (CH300CCH2-), carbomethoxy-ethyl (CH300CC2H4-), carboethoxyllle-thyl (C2ll500CCH2-) and carboethoxyethyl (C2H500CC2H4 ~ etc. The carbamoyla~kyl groups are desirably thosè in which the alkyl group has 1 to 4 carbon atoms, including carbamoylmethyl (~l2NCOCH2-) and carbamoylethyl (H2NCOC2H~-) e-tc. The alkoxy groups are desirably those haviny 1 to 5 carbon atoms, including methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy anc1 pentoxy etc. The hydroxyalkyl groups are desirably those.in which ~le alk~l ~roup has 1 to 7 carbon atoms, inclu-diny hydroxymethyl and 1-hydroxy-propyl-2,1-hydroxy-ethyl-2,1-hydroxy-2-metl1yl-propyl-2 e-tc. The acyl 1 groups are desirably those having 1 to ~ carbon atoms, including formyl, acetyl, propionyl, butylyl an~ isobuty-lyl etc. T~le acyloxy groups are desirably those in which the acyl group has 1 to 4 carbon atoms, including ~or-myloxy, acetyloxy, propionyloxy, butylyloxy, and iso-butylyloxy etc. The aryl groups include phenyl, tolyl and naphthyl etc. The aryloxy groups include phenyloxy, tolyloxy and naphthyloxy etc. The alkylthio groups are desirably those in which the aLkyl group has 1 to 4 carbon atoms, including methylthio, ethylt}lio and propylthio etc The alkylsulfinyl groups are desirably those having l to 6 carbon atoms, including methylsulfinyl, ethylsulfi-nyl and propylsulfinyl e-tc.
The ring A is not substituted or is substituted at the 4- or 5-position particularly desirably with alkyl, halogen, trifluoromethyl or alkoxy among the substituents described above.
The N-protective groups represen-ted by R1 include alkyl, acyl, carboalkoxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, alkylcarbonylmethyl, alkoxycarbonyl-me-thyl and alkylsulfonyl etc. The alkyl groups are desirably those having 1 to 5 carbon atoms, including methyl, ethyl, propyl, isopropyl, butyl, isobutyl and pentyl etc. The acyl groups include the same ~roups as those described ~or the substituents o~ the ring ~. The carboalko~y groups include the same groups as those described for the substituents of the ring A. The alkylcarbamoyl groups are represented by the Eormula:
}~
alkyl wherein the alkyl group has desirably 1 to ~ carbon atoms, includlng me-thylcarbamoyl, ethylcarbamoyl, propylcarba-moyl and isopropylcarbamoyl e~c. The dialykylcarbamoyl 5 groups are r~presented by the formula:
allcyl\
alkyi/
.. . .. .
~L~
1 wherein the ~lkyl groups have desirably 1 to 4 carbon ~toms each, includin~ dimethylcarbamoyl, dietllylcarbamoyl and N-methyl-N-ethylcarbamoyl e-tc. The alkylcarbonyl-methyl groups are represented by the Eormula: alkyl-CO-C1~2- wherein the alkyl group has desirably 1 to 4 carbon atoms, including acetylmethyl and propionylmethl etc.The alkoxycarbonylmethyl groups are represen-ted by the formula: alkyl-OCO-CH2- wherein the alkyl group h~s desir-ably 1 to 4 carbon atoms, including methoxycarbonylmethyl, ethoxycarbonylmethyl and propoxycarbonylmethyl etc. The alkylsulfonyl groups are represented by -the formula:
alkyl-SO2- wherein the alkyl group has desirably 1 to 4 carbon atoms, including methylsulfonyl, ethylsulfonyl, propylsulfonyl and isopropylsulfonyl etc.
The alkyl groups which may be fluorinate~ repre-sented by R2, R3 and R4, have desirably 1 to 4 carbon atoms each. Such unsubsti.tuted alkyl groups include methyl, ethyl, propyl, isopropyl, butyl and isobutyl etc.
Such Eluorinated alkyl groups include trifluoromethyl,
2,2,2-trifluoroethyl, 2,2,3,3,3,-pentafluoropropyl, 1-(trifluoromethyl)-2,2,2-tri~luoroethyl, 2,2,3,3-tetra-fluoropropyl and 2,2,3,3,4,4,4-heptafluorobutyl etc.
The alkoxy groups which may be fluorinated, repre-s~nted hy R2, R3 and R4, have ~esirably 1 to 8 carbon atoms each. Such unsubstituted alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, pentoxy, hexyloxy, heptyloxy and octyloxy. Such fluori-nated alkoxy groups include 2,2,2-tri-~luoroethoxy, 2,2,3 t 3,3,-pentafluoropropoxy, 1-(tri1uoromethyl)-2,2,2-tri~luoroethoxy, 2,2,3,3-tetra~luoropropoxy, 2,2,3,3,4,4,4~hepta~1uorobutoxy and 2,2,3,3,4,4,5,5-octa-fluoropentoxy.
In more detail about the compounds ~I) and (II), it is pa~ticul~rl~ desirable that the ring ~ is unsubstituted or substituted at the 4- or 5-position wlth methoxy or trifluoromethyl, R1 ts a hydro~en atom, R2 and R~ are . . : -~ . .
, .
~,6~
1 independen-tly hydrogen atom or methyl and ~3 is a fluorinated alkoxy h~ving 2 to 5 carbol~ atoms.
The vanadium compounds used in this invention include vanadium pentaoxide (V2O5), sodium metavanadate (NaVO3), ammonium metavanadate (NH4V03~ and vanadium (IV) acetyl-acetonate [(CH3COC1l2COCH2)2VO], desirably vanadium penta-oxide, sodium metavanadate and vanadium acetylacetonate.
The amount of -tha vanadium compounds used is generally about 0.01 to 10 mole%, desirably about 0.05 to 2 mole~, particularly desirably about 0.1 to 0.5 mole%
relative to one mole of the compound (I).
Hydrogen peroxide is usually used in an aqueous solution of hydrogen peroxide, but a solution in an orga- `
nic solvent such as n-butylalcohol and a solution in the mi~ture o~ said organic solvent and water may also be used.
The concentration of hydrogen peroxide used in usually lO to 70%, desirably 20 to 40~, but should not be limited only to these ranges.
The amount oE hydrogen peroxide used is usually a slight excess relatlve to olle equivalent of the compound (I), ~0 desirably about 1 to 3 equivalents, more desirably about 1 to 1.5 equivalents.
The solvents used ~or the reaction include haloge-nated hydrocarbons such as chloroform and dichloromethane, ethers such as tetrahydrofuran and dioxane, alcohols such as ethanol, methanol and isopropanol, ketones such as acetone and methyleth~lketone, ~itriles such as aceto-nitrile and water, among which ethanol, methanol, acetone and acetonl-trile are desirable and ethanol is more desir-able. These solven-ts may be used singly or in combi-nation. The amount of the solvent used ~or the reactionis abou-t 0.5 to lO l, desirably about l to 5 l, relative to one mole of the compound (I~, but should no-t be limi-ted only to these ranges.
The re~ction temperature is usually the temperature 35 und~r ice~coollrlg to a~out the boiling point o~ the sol-vent~" usually the temperature under ice~cooling to about 7 ~ 3 3~
1 40C, more desirably about 15 to 30C.
The reaction time is usually about 0.5 to 24 hours, desirably about 1 to 8 hours.
The desired compound (II) produced by tlle reaction described above is usually separated out as crystals from -the reaction mixture, so that the crystals can be collect-ed by filtration after decomposi-tion of the excess of hydrogen peroxide remaining after the reaction by addition of an aqueous solution of sodium thiosulfate, but the crystals may also be collected by extraction with a sol-vent such as chloroform if necessary, followed by concentration~
The crystals thus collec-ted can be purified if neces-sary by a routine method such as recrystallization and chromatography.
The starting compounds (I) can be produced by the methods described in, for example, U.S. Patent No.4255431, European Patent Laid-Open No.45200, No.74341, No.80602, No.5129, No.174726, No.175464 and Great sri-tain Patent Laid-Open No.2l34523A, etc.
According to the method for production of ~s invention, 2-(2-pyridylmethylsulfinyl)benzLmldazole can be cbtained in a good yield (about 85% or more) and with low production of by-products such as 2-(~-pyridylmethylsulfonyl)benzLmidazole N-oxlde~
This invention is illustrated in more detail; in the 2S following Working ~xamples and Refere~ce Example.
Example l 2-[[3-Methyl-4-(2,2,2-tri~luoroethoxy)pyrid-2-yl]-methylthio]benzimidazole (monohydrate) (1.77 g) was dis-solved in dichloromethane (30 ml), to which was added dropwise a-t 15-20C a solut1On of hydrogen peroxide in t-butanol (2.75 ml corresponding to 0.2 g of hydrogen per-oxide~ containing vanadium pentaoxide (5 mg), and then allowed to react at 20-25C ~or about one hour. After completion of the reac-tion,an aqueous solution of sodium thiosulEate (0.5 g/30 ml) was added to the reaction mix-ture, which was stirred vigorously Eor about 10 minutes, allowed to stand still, and separated into layers. 'rhe dichlorolllethane layer was washed with wa~er (30 ml), and concentrated under reduced pressure; to the residue was I
~3~
1 added a mixture of ethanol-water (9:1, 10 ml) Eor crystal~
lization. This solution was ice-cooled, and the crystals were collected by filtration and washed with an ice-cooled mixture o ethanol-water (8 2). The crystals thus ob-tained were treated with a mixture of ethanol-water (9:1, ml), heated (65-70C) and s-tirred for dissolu-tion of the crystals, then the insoluble matters were removed by hot filtration. The filtrate was ice-cooled for crystalliza-tion, and the crystals were collected by filtration, washed with ice-cooled ethanol-water mixture (8:2) and dried in vaccuo to give white crystals of 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyrid-2-yl]me-thylsulfinyl]benz-imidazole ~1.64 g). (yield: 93.2~).
m.p. 177-178C (decomposed) Example 2 2-[[3-Methyl-~-(2,2,2-trifluoroethoxy)pyrid-2-yl]-metllylthio]benzimidazole (monohydrate) (10.0 g) was dis-solved in ethanol (75 ml)l to which was added a solution of sodium metavanadate (15 mg) in 3~% aqueous solution of hydro~en peroxide(3.07 c3), and allowed to react by stirring at 20-25 for about 8 hours. After completion of the reaction an aqueous solution of sodium thiosulfate (1 g/5 ml) was added to the reaction mixture, which was stirred vigorous-ly for about 10 minutes The crystals were collected by filtration and washed with an ice-cooled mixture of etha-nol-water (1:1). The crystals thus ~btained were -treated with a mixture of ethanol-water (9 1, 50 ml), heated (65-70C) and stirred so -that the crystals were di~solved, then the insoluble ma-tters were removed by ho-t filtra-tlon. The fLltrate was ice cooled Eor crystalliza-tion, and the crystals were collected by Eiltration, washed with ice-cooled ethanol~water mixture (8:2) and dried~ in vaccuo, to cJiVe white needles Gf 2-[[3-methyl-4-(2,2,2-tri~luoroethoxy)pyrld 2-yl]methylsulfinyl]benzimidazole (9.0 CJ). (yield: 90.5'~).
m.p. 177-17a~C (decomposed) c~
_ 9 _ 1 Example 3 2-[[3-Methyl-4-(2,2,2-trifluoroethoxy)pyrid-2-yl]-methylthiojbenzimi~azole (monohydrate) (20.0 g) was dis-solved in ethanol (150 ml), to which was added dropwise at about 20C a solution of vanadium pentaoxide (30 mg) in a mixture of 35~; a~lueous solution of hydrogen peroxide (6 .14 g) and ethanol (6 ml), and allowed to react at 18-22 for about 2.5 hours. After completion of the reaction an aqueous solution of sodium thiosulfate (2 g/60 ml) was added to -the reaction mixture, which was stirred by ice-cooling for about 1 hour. The crystals were collected by filtration .
and washed with an ice-cooled mixture of ethanol-water ~1:1). The crystals thus obtained were treated with a mixture of ethanol-water (9:1, 100 ml), heated (7o-8ooc)and stirred so that the crystals were dissolved, then the insoluble ma-tters were removed by hot fil-tration. The filtrate was lce-cooled for crystallization, and the crystals were collected by filtra-tion, washed with ice-cooled ethanol-water mixture (8:2) and dried in vaccuo, to give white needles of 2-[[3-methyl-4-(2,2,2 trifluoro-ethoxy)pyrid-2-yl]methylsulfinyl]benzimidazole (17.% g).
(yield: 89.5%).
m.p. 177-178C (decomposed) Example 4 Vanadium(IV) acetylacetonate (40 mg) was dissolved in ethanol (150 ml), to which 2-[[3-methyl-4-(2,2,2-tri-fluoroethoxy)pyr.td-2-ylimethylthio]benzimidazole (monohydrate) (20.0 g) was added and then 35~ aqueous solution of hydrogen peroxide (5.14 g) was added dropwise at Z0-25C, and the mixture was allowed to react at 20-25C ~or about 5 hours. After completion of the reaction, a solution o sodium thlosulfate (2.7 g/16 ml) was added to the reaction rnixture and sti.rred vigorously for about 10 minutes- The crystals were collected by filtration and washed wlth an ice-coo:led m:lxture o eth~nol-w~ter (8:2). The crystals thus obt~irled we.re treated w:lth a mixture of ethanol-water
The alkoxy groups which may be fluorinated, repre-s~nted hy R2, R3 and R4, have ~esirably 1 to 8 carbon atoms each. Such unsubstituted alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, pentoxy, hexyloxy, heptyloxy and octyloxy. Such fluori-nated alkoxy groups include 2,2,2-tri-~luoroethoxy, 2,2,3 t 3,3,-pentafluoropropoxy, 1-(tri1uoromethyl)-2,2,2-tri~luoroethoxy, 2,2,3,3-tetra~luoropropoxy, 2,2,3,3,4,4,4~hepta~1uorobutoxy and 2,2,3,3,4,4,5,5-octa-fluoropentoxy.
In more detail about the compounds ~I) and (II), it is pa~ticul~rl~ desirable that the ring ~ is unsubstituted or substituted at the 4- or 5-position wlth methoxy or trifluoromethyl, R1 ts a hydro~en atom, R2 and R~ are . . : -~ . .
, .
~,6~
1 independen-tly hydrogen atom or methyl and ~3 is a fluorinated alkoxy h~ving 2 to 5 carbol~ atoms.
The vanadium compounds used in this invention include vanadium pentaoxide (V2O5), sodium metavanadate (NaVO3), ammonium metavanadate (NH4V03~ and vanadium (IV) acetyl-acetonate [(CH3COC1l2COCH2)2VO], desirably vanadium penta-oxide, sodium metavanadate and vanadium acetylacetonate.
The amount of -tha vanadium compounds used is generally about 0.01 to 10 mole%, desirably about 0.05 to 2 mole~, particularly desirably about 0.1 to 0.5 mole%
relative to one mole of the compound (I).
Hydrogen peroxide is usually used in an aqueous solution of hydrogen peroxide, but a solution in an orga- `
nic solvent such as n-butylalcohol and a solution in the mi~ture o~ said organic solvent and water may also be used.
The concentration of hydrogen peroxide used in usually lO to 70%, desirably 20 to 40~, but should not be limited only to these ranges.
The amount oE hydrogen peroxide used is usually a slight excess relatlve to olle equivalent of the compound (I), ~0 desirably about 1 to 3 equivalents, more desirably about 1 to 1.5 equivalents.
The solvents used ~or the reaction include haloge-nated hydrocarbons such as chloroform and dichloromethane, ethers such as tetrahydrofuran and dioxane, alcohols such as ethanol, methanol and isopropanol, ketones such as acetone and methyleth~lketone, ~itriles such as aceto-nitrile and water, among which ethanol, methanol, acetone and acetonl-trile are desirable and ethanol is more desir-able. These solven-ts may be used singly or in combi-nation. The amount of the solvent used ~or the reactionis abou-t 0.5 to lO l, desirably about l to 5 l, relative to one mole of the compound (I~, but should no-t be limi-ted only to these ranges.
The re~ction temperature is usually the temperature 35 und~r ice~coollrlg to a~out the boiling point o~ the sol-vent~" usually the temperature under ice~cooling to about 7 ~ 3 3~
1 40C, more desirably about 15 to 30C.
The reaction time is usually about 0.5 to 24 hours, desirably about 1 to 8 hours.
The desired compound (II) produced by tlle reaction described above is usually separated out as crystals from -the reaction mixture, so that the crystals can be collect-ed by filtration after decomposi-tion of the excess of hydrogen peroxide remaining after the reaction by addition of an aqueous solution of sodium thiosulfate, but the crystals may also be collected by extraction with a sol-vent such as chloroform if necessary, followed by concentration~
The crystals thus collec-ted can be purified if neces-sary by a routine method such as recrystallization and chromatography.
The starting compounds (I) can be produced by the methods described in, for example, U.S. Patent No.4255431, European Patent Laid-Open No.45200, No.74341, No.80602, No.5129, No.174726, No.175464 and Great sri-tain Patent Laid-Open No.2l34523A, etc.
According to the method for production of ~s invention, 2-(2-pyridylmethylsulfinyl)benzLmldazole can be cbtained in a good yield (about 85% or more) and with low production of by-products such as 2-(~-pyridylmethylsulfonyl)benzLmidazole N-oxlde~
This invention is illustrated in more detail; in the 2S following Working ~xamples and Refere~ce Example.
Example l 2-[[3-Methyl-4-(2,2,2-tri~luoroethoxy)pyrid-2-yl]-methylthio]benzimidazole (monohydrate) (1.77 g) was dis-solved in dichloromethane (30 ml), to which was added dropwise a-t 15-20C a solut1On of hydrogen peroxide in t-butanol (2.75 ml corresponding to 0.2 g of hydrogen per-oxide~ containing vanadium pentaoxide (5 mg), and then allowed to react at 20-25C ~or about one hour. After completion of the reac-tion,an aqueous solution of sodium thiosulEate (0.5 g/30 ml) was added to the reaction mix-ture, which was stirred vigorously Eor about 10 minutes, allowed to stand still, and separated into layers. 'rhe dichlorolllethane layer was washed with wa~er (30 ml), and concentrated under reduced pressure; to the residue was I
~3~
1 added a mixture of ethanol-water (9:1, 10 ml) Eor crystal~
lization. This solution was ice-cooled, and the crystals were collected by filtration and washed with an ice-cooled mixture o ethanol-water (8 2). The crystals thus ob-tained were treated with a mixture of ethanol-water (9:1, ml), heated (65-70C) and s-tirred for dissolu-tion of the crystals, then the insoluble matters were removed by hot filtration. The filtrate was ice-cooled for crystalliza-tion, and the crystals were collected by filtration, washed with ice-cooled ethanol-water mixture (8:2) and dried in vaccuo to give white crystals of 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyrid-2-yl]me-thylsulfinyl]benz-imidazole ~1.64 g). (yield: 93.2~).
m.p. 177-178C (decomposed) Example 2 2-[[3-Methyl-~-(2,2,2-trifluoroethoxy)pyrid-2-yl]-metllylthio]benzimidazole (monohydrate) (10.0 g) was dis-solved in ethanol (75 ml)l to which was added a solution of sodium metavanadate (15 mg) in 3~% aqueous solution of hydro~en peroxide(3.07 c3), and allowed to react by stirring at 20-25 for about 8 hours. After completion of the reaction an aqueous solution of sodium thiosulfate (1 g/5 ml) was added to the reaction mixture, which was stirred vigorous-ly for about 10 minutes The crystals were collected by filtration and washed with an ice-cooled mixture of etha-nol-water (1:1). The crystals thus ~btained were -treated with a mixture of ethanol-water (9 1, 50 ml), heated (65-70C) and stirred so -that the crystals were di~solved, then the insoluble ma-tters were removed by ho-t filtra-tlon. The fLltrate was ice cooled Eor crystalliza-tion, and the crystals were collected by Eiltration, washed with ice-cooled ethanol~water mixture (8:2) and dried~ in vaccuo, to cJiVe white needles Gf 2-[[3-methyl-4-(2,2,2-tri~luoroethoxy)pyrld 2-yl]methylsulfinyl]benzimidazole (9.0 CJ). (yield: 90.5'~).
m.p. 177-17a~C (decomposed) c~
_ 9 _ 1 Example 3 2-[[3-Methyl-4-(2,2,2-trifluoroethoxy)pyrid-2-yl]-methylthiojbenzimi~azole (monohydrate) (20.0 g) was dis-solved in ethanol (150 ml), to which was added dropwise at about 20C a solution of vanadium pentaoxide (30 mg) in a mixture of 35~; a~lueous solution of hydrogen peroxide (6 .14 g) and ethanol (6 ml), and allowed to react at 18-22 for about 2.5 hours. After completion of the reaction an aqueous solution of sodium thiosulfate (2 g/60 ml) was added to -the reaction mixture, which was stirred by ice-cooling for about 1 hour. The crystals were collected by filtration .
and washed with an ice-cooled mixture of ethanol-water ~1:1). The crystals thus obtained were treated with a mixture of ethanol-water (9:1, 100 ml), heated (7o-8ooc)and stirred so that the crystals were dissolved, then the insoluble ma-tters were removed by hot fil-tration. The filtrate was lce-cooled for crystallization, and the crystals were collected by filtra-tion, washed with ice-cooled ethanol-water mixture (8:2) and dried in vaccuo, to give white needles of 2-[[3-methyl-4-(2,2,2 trifluoro-ethoxy)pyrid-2-yl]methylsulfinyl]benzimidazole (17.% g).
(yield: 89.5%).
m.p. 177-178C (decomposed) Example 4 Vanadium(IV) acetylacetonate (40 mg) was dissolved in ethanol (150 ml), to which 2-[[3-methyl-4-(2,2,2-tri-fluoroethoxy)pyr.td-2-ylimethylthio]benzimidazole (monohydrate) (20.0 g) was added and then 35~ aqueous solution of hydrogen peroxide (5.14 g) was added dropwise at Z0-25C, and the mixture was allowed to react at 20-25C ~or about 5 hours. After completion of the reaction, a solution o sodium thlosulfate (2.7 g/16 ml) was added to the reaction rnixture and sti.rred vigorously for about 10 minutes- The crystals were collected by filtration and washed wlth an ice-coo:led m:lxture o eth~nol-w~ter (8:2). The crystals thus obt~irled we.re treated w:lth a mixture of ethanol-water
3~
-- 10 ~
.
l (9-1, 90 ml), heated (60-70C) and stirred so th~t the crys-tals were disso]ved, then the insoluble matters were removed by hot filtr~tion. The filtrate was ice-cooled for crystallization and the crystals were collected by filtxation, washed with ice-cooled ethanol-water mixture (8:2) and dried in vaccuo, to give white needles of 2-~[3-methyl-4-(2~2r2-trifluoroethoxy)pyridr2-yl]methylsul-finyl]benzimidazole (18.1 g). (yield: 91.0%).
m.p. 177-178C (decomposed) Example 5 Each 2-[[3-methyl-4-(2t2~2-trifluoroethoxy)pyrid-2 yl]methylsulfinyl~benzimidazole obtained in Exam-ples 1-4 and in Reference Example described below was analyzed by high performance liquid chromatography (HPLC) and the following results were obtained.
Conditions of I~PLC
Equipment used:Shimadzu*~igh Performance Liquid Chromato-graph Type LC-6A
Detector: Shimadzu Ultraviolet Absorption Photometer Type SPD-6A, measurement wave length: 254 nm Data processor: ShimadzuType CR-3A
Column: Nucleosil 5C18 (150 x 40 mm i.d.) Column temperature: a fixed tempera-ture of about 25C
Mobile phase: A mixture of methanol-water-triethylamine (60~40:1) of which pH has been adjusted to 7.0 by addition of phosphoric acid.
Flow rate: 0.7 ml /Inin .
Time required for analysis: 30 minutes Compound Area percentage (%) in high performance liquid chromatography Exam- Exam- Exam- Exam- ReEerence _ _ ple 1 ple 2 ple 3 ple 4 Example sulfoxide derivative 1) 99 3 99.6 ~9.699.7 sa. 9 ~5 N-oxide derivative 2) 0.1 <0 1 <0.l~0,1 O.fi **rrrR(lemark --; ~
.....
::
*1 ) C OC112c~3 ~ J ~ CII.
*2) OCII 2 Cl~ 3 ~N~ Cll~Y~3 1, ~ .
Example 6 According -to the same method as in Example 4, the following compounds were produced and analyzed by HPLC
under the same conditions as in Example 5; the results are summarized as follows.
I~N,~L 11 Cll 2 ~ R ~
o R' , q~
-- 12 ~
-r~ V V V V V
~^
~ u~
~ X ~
~ ~ .
O ~ V~
:~ V V V ~ V V C~ n . ~t~ n ~ ~ _ _ _ t-- ~n co In ~co ~q_ _ .
n n n 1 n ~
r~ ~~ n n n ~ ~
cc ~ ~ cO~ o O
N n n n n _ n n ~ 0 ~0 ~ ~ n n ~a ' " '' , . ' ' . ' .~. ~ ' ~. ; -~2~
~, ~N~ C112~ N~LII ;
I I O 11' U
10 3i~ )dccompos i ~ ion Re~erenGe Example 2-[[3-Methyl-4-t2,2,2-trifluoroethoxy)pyrid-2-yl]methylth.to]benzimida.zole (monohydrate) (20 g) was dissolved in chloroform (200 ml), to which was added slowly dropwise below S C a solution of m-chloroper-benzoic acid (13.5 g) in chloroform (200 ml), and stirred at the same temperature for about 10 minutes. A~ter completion of -the reaction,the reaction mixture was washed wi-th a solution o~ sodium hydrogencarbonate, and dried : over magnesium sulfate, and chloroform was evaporated oE
under reduced pressure. To tha residue was added ethanol (100 ml) ~or crystallization; which was ice-cooled: the resulting crystals were collect~d by filtration and washed with ice-cooled ethanol. The crystals thus obtained were treated with a mixture of ethanol-water (9:1, 90 ml), ~0 heated (65-70C).and stirred SQ that the crys-taIs were dissolved, then the insoluble ma-tters were removed by hot Eiltration. The filtrate was ice-cooled ~or crystal-lization and the crystals we.re collected by filtration, washed wlth ice-cooled ethanol-water mixture (~:2), and dried in vaccuo, to glve white needles o~ 2-[~3-methyl-4-~2,2,2-trl~luoroethoxy)pyrld-2-yl]methylsulEinyl3benz-1 imidazole (14.9 g, yield: 74.9%).
m.p. 177-178C (decomposed) ' .
-~;
'' . ' ' ~ ~ .
-- 10 ~
.
l (9-1, 90 ml), heated (60-70C) and stirred so th~t the crys-tals were disso]ved, then the insoluble matters were removed by hot filtr~tion. The filtrate was ice-cooled for crystallization and the crystals were collected by filtxation, washed with ice-cooled ethanol-water mixture (8:2) and dried in vaccuo, to give white needles of 2-~[3-methyl-4-(2~2r2-trifluoroethoxy)pyridr2-yl]methylsul-finyl]benzimidazole (18.1 g). (yield: 91.0%).
m.p. 177-178C (decomposed) Example 5 Each 2-[[3-methyl-4-(2t2~2-trifluoroethoxy)pyrid-2 yl]methylsulfinyl~benzimidazole obtained in Exam-ples 1-4 and in Reference Example described below was analyzed by high performance liquid chromatography (HPLC) and the following results were obtained.
Conditions of I~PLC
Equipment used:Shimadzu*~igh Performance Liquid Chromato-graph Type LC-6A
Detector: Shimadzu Ultraviolet Absorption Photometer Type SPD-6A, measurement wave length: 254 nm Data processor: ShimadzuType CR-3A
Column: Nucleosil 5C18 (150 x 40 mm i.d.) Column temperature: a fixed tempera-ture of about 25C
Mobile phase: A mixture of methanol-water-triethylamine (60~40:1) of which pH has been adjusted to 7.0 by addition of phosphoric acid.
Flow rate: 0.7 ml /Inin .
Time required for analysis: 30 minutes Compound Area percentage (%) in high performance liquid chromatography Exam- Exam- Exam- Exam- ReEerence _ _ ple 1 ple 2 ple 3 ple 4 Example sulfoxide derivative 1) 99 3 99.6 ~9.699.7 sa. 9 ~5 N-oxide derivative 2) 0.1 <0 1 <0.l~0,1 O.fi **rrrR(lemark --; ~
.....
::
*1 ) C OC112c~3 ~ J ~ CII.
*2) OCII 2 Cl~ 3 ~N~ Cll~Y~3 1, ~ .
Example 6 According -to the same method as in Example 4, the following compounds were produced and analyzed by HPLC
under the same conditions as in Example 5; the results are summarized as follows.
I~N,~L 11 Cll 2 ~ R ~
o R' , q~
-- 12 ~
-r~ V V V V V
~^
~ u~
~ X ~
~ ~ .
O ~ V~
:~ V V V ~ V V C~ n . ~t~ n ~ ~ _ _ _ t-- ~n co In ~co ~q_ _ .
n n n 1 n ~
r~ ~~ n n n ~ ~
cc ~ ~ cO~ o O
N n n n n _ n n ~ 0 ~0 ~ ~ n n ~a ' " '' , . ' ' . ' .~. ~ ' ~. ; -~2~
~, ~N~ C112~ N~LII ;
I I O 11' U
10 3i~ )dccompos i ~ ion Re~erenGe Example 2-[[3-Methyl-4-t2,2,2-trifluoroethoxy)pyrid-2-yl]methylth.to]benzimida.zole (monohydrate) (20 g) was dissolved in chloroform (200 ml), to which was added slowly dropwise below S C a solution of m-chloroper-benzoic acid (13.5 g) in chloroform (200 ml), and stirred at the same temperature for about 10 minutes. A~ter completion of -the reaction,the reaction mixture was washed wi-th a solution o~ sodium hydrogencarbonate, and dried : over magnesium sulfate, and chloroform was evaporated oE
under reduced pressure. To tha residue was added ethanol (100 ml) ~or crystallization; which was ice-cooled: the resulting crystals were collect~d by filtration and washed with ice-cooled ethanol. The crystals thus obtained were treated with a mixture of ethanol-water (9:1, 90 ml), ~0 heated (65-70C).and stirred SQ that the crys-taIs were dissolved, then the insoluble ma-tters were removed by hot Eiltration. The filtrate was ice-cooled ~or crystal-lization and the crystals we.re collected by filtration, washed wlth ice-cooled ethanol-water mixture (~:2), and dried in vaccuo, to glve white needles o~ 2-[~3-methyl-4-~2,2,2-trl~luoroethoxy)pyrld-2-yl]methylsulEinyl3benz-1 imidazole (14.9 g, yield: 74.9%).
m.p. 177-178C (decomposed) ' .
-~;
'' . ' ' ~ ~ .
Claims (13)
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A method for producing a compound having the formula:
(II) (wherein the ring A may be substituted; R1 is a hydrogen atom or an N-protective group; R2, R3 and R4 are independently hydrogen atom, an alkyl group which may be fluorinated or an alkoxy group which may be fluorinated), which comprises subjecting a compound having the formula (I) (wherein A, R1, R2, R3 and R4 are the same as described above), to oxidation with hydrogen peroxide in the presence of a vanadium compound.
(II) (wherein the ring A may be substituted; R1 is a hydrogen atom or an N-protective group; R2, R3 and R4 are independently hydrogen atom, an alkyl group which may be fluorinated or an alkoxy group which may be fluorinated), which comprises subjecting a compound having the formula (I) (wherein A, R1, R2, R3 and R4 are the same as described above), to oxidation with hydrogen peroxide in the presence of a vanadium compound.
2. A method according to claim 1, wherein the sub-stituent of the ring A is C1-7 alkyl, halogen, cyano, carboxy, carbo-C1-4 alkoxy, carbo-C1-4 alkoxy-C1-4 alkyl, carbamoyl, carbamoyl-C1-4 alkyl, hydroxy, C1-5 alkoxy, hydroxy-C1-7 alkyl, trifluoromethyl, C1-4 acyl, carbamoyl-oxy, nitro, C1-4 acyl-oxy, aryl, aryloxy, C1-4 alkyl-thio or C1-6 alkyl-sulfinyl.
3. A method according to claim 1, whe.rein the N-protective group is C1-5 alkyl, C1-4 acyl, carbo-C1-4 alkoxy, carbomoyl, C1-4 al]cyl-carbamoyl, di(C-4 alkyl)-carbamoyl, C1-4 alkyl-carbonylmethyl, C1-4 alkoxy-carbonylmethyl or C1-4 alkyl-sulfonyl.
4. A method according to claim 1, wherein R2, R3 and R4 are independently C1-4 alkyl which may be fluorinated or C1-8 alkoxy which may be fluorinated.
5. A method according to claim 1, wherein the ring A is unsubstituted or substituted at the 4- or 5-position with methoxy or trifluoromethyl, R1 is hydrogen, R2 and R4 are independently hydrogen or methyl and R3 is a fluorinated C2-5 alkoxy.
6. A method according to claim 1, wherein the vanadium compound is vanadium pentaoxide, sodium metavanadate, ammonium metavanadate or vanadium (IV) acetylacetonate.
7. A method according to claim 1, wherein the vanadium compound is used in an amount of about 0.01 to 10 mole %
relative to the compound having the formula:
(I)
relative to the compound having the formula:
(I)
8. A method according to claim 1, wherein hydrogen peroxide is used in an amount of about 1 to 3 equivalents relative to the compound having the formula:
(I)
(I)
9. A method according to claim 2 or 3, wherein R2, R3 and R4 are independently C1-4 alkyl which may be fluorinated or C1-8 alkoxy which may be fluorinated.
10. A method according to claim 2, 3 or 4, wherein the ring A is unsubstituted or substituted at the 4- or 5-position with methoxy or trifluoromethyl, R1 is hydrogen, R2 and R4 are in-dependently hydrogen or methyl and R3 is a fluorinated C2-5 alkoxy.
11. A method according to claim 5, 7 or 8, wherein the vanadium compound is vanadium pentaoxide, sodium metavanadate, ammonium metavanadate or vanadium (IV) acetylacetonate.
12. A method according to claim 2, 3 or 5, wherein the vanadium compound is vanadium pentaoxide, sodium metavanadate, ammonium metavanadate or vanadium (IV) acetylacetonate; the vanadium compound is used in an amount of about 0.01 to 10 mole %
relative to the compound of the formula (I); and hydrogen peroxide is used in an amount of about 1 to 3 equivalents relative to the compound of the formula (I).
relative to the compound of the formula (I); and hydrogen peroxide is used in an amount of about 1 to 3 equivalents relative to the compound of the formula (I).
13. A method according to claim 2, 3 or 5, wherein the vanadium compound is vanadium pentaoxide, sodium metavanadate, ammonium metavanadate or vanadium (IV) acetylacetonate; the vanadium compound is used in an amount of about 0.05 to 2 mole %
relative to the compound of the formula (I); hydrogen peroxide is used in an amount of about 1 to 3 equivalents relative to the com-pound of the formula (I) using a solvent selected from the class consisting of halogenated hydrocarbon solvents, ether solvents, alcohol solvents, ketone solvents, nitrile solvents, water and mixtures thereof; and the oxidation reaction is carried out at an ice-cooling temperature to about 40°C.
relative to the compound of the formula (I); hydrogen peroxide is used in an amount of about 1 to 3 equivalents relative to the com-pound of the formula (I) using a solvent selected from the class consisting of halogenated hydrocarbon solvents, ether solvents, alcohol solvents, ketone solvents, nitrile solvents, water and mixtures thereof; and the oxidation reaction is carried out at an ice-cooling temperature to about 40°C.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP194809/1987 | 1987-08-04 | ||
| JP19480987 | 1987-08-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1263119A true CA1263119A (en) | 1989-11-21 |
Family
ID=16330618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000573673A Expired CA1263119A (en) | 1987-08-04 | 1988-08-03 | Production of 2-(2- pyridylmethylsulfinyl)benzimidazole compounds |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5578732A (en) |
| EP (1) | EP0302720B1 (en) |
| KR (1) | KR960000047B1 (en) |
| AT (1) | ATE82283T1 (en) |
| CA (1) | CA1263119A (en) |
| DE (1) | DE3875848T2 (en) |
| DK (1) | DK171989B1 (en) |
| ES (1) | ES2052728T3 (en) |
| GR (1) | GR3006974T3 (en) |
| HU (1) | HU199828B (en) |
| IE (1) | IE61717B1 (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995012590A1 (en) | 1993-11-04 | 1995-05-11 | Torcan Chemical Ltd. | Preparation of omeprazole and lansoprazole and intermediates useful therein |
| US6077541A (en) * | 1997-11-14 | 2000-06-20 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
| US6121454A (en) * | 1997-05-06 | 2000-09-19 | Pdi-Research Laboratories, Inc. | Synthesis of pharmaceutically useful pyridine derivatives |
| US6174548B1 (en) | 1998-08-28 | 2001-01-16 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
| US6437139B1 (en) | 1997-05-06 | 2002-08-20 | Pdi-Research Laboratories, Inc. | Synthesis of pharmaceutically useful pyridine derivatives |
| US6733778B1 (en) | 1999-08-27 | 2004-05-11 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
| US7129358B2 (en) | 2001-02-02 | 2006-10-31 | Teva Pharmaceutical Industries Ltd. | Processes for the production of substituted 2-(2-pyridylmethyl) sulfinyl-1H-benzimidazoles |
| WO2010134099A1 (en) | 2009-05-21 | 2010-11-25 | Cadila Healthcare Limited | One pot process for preparing omeprazole and related compounds |
| WO2013108068A1 (en) | 2012-01-21 | 2013-07-25 | Jubilant Life Sciences Limited | Process for the preparation of 2-pyridinylmethylsulfinyl benzimidazoles, their analogs and optically active enantiomers |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK171989B1 (en) * | 1987-08-04 | 1997-09-08 | Takeda Chemical Industries Ltd | Process for the preparation of 2- (2-pyridylmethylsulfinyl) benzimidazoles |
| SE8804629D0 (en) * | 1988-12-22 | 1988-12-22 | Ab Haessle | NEW THERAPEUTICALLY ACTIVE COMPOUNDS |
| CA2053527C (en) | 1990-10-17 | 2002-03-12 | Takashi Sohda | Pyridine derivatives, their production and use |
| ES2026761A6 (en) * | 1990-10-31 | 1992-05-01 | Genesis Para La Investigacion | A process for the preparation of omeprazol. |
| NZ244301A (en) * | 1991-09-20 | 1994-08-26 | Merck & Co Inc | Preparation of 2-pyridylmethylsulphinylbenzimidazole and pyridoimidazole derivatives from the corresponding sulphenyl compounds |
| BR9306702A (en) * | 1992-07-08 | 1998-12-08 | Monsanto Co | Benzimidazoles to relieve stomach ulcers in pigs |
| ES2060541B1 (en) * | 1993-02-26 | 1995-11-16 | Vinas Lab | NEW PROCEDURE FOR THE SYNTHESIS OF A DERIVATIVE OF 2- (2-PIRIDILMETILSUFINIL) BENCIMIDAZOLE, AND NEW INTERMEDIATE PRODUCTS OBTAINED WITH THE SAME. |
| ES2063705B1 (en) * | 1993-06-14 | 1995-07-16 | S A L V A T Lab Sa | INTERMEDIATE FOR THE SYNTHESIS OF LANSOPRAZOLE AND ITS PROCEDURE FOR OBTAINING. |
| TW385306B (en) * | 1996-11-14 | 2000-03-21 | Takeda Chemical Industries Ltd | Method for producing crystals of benzimidazole derivatives |
| KR100458170B1 (en) * | 1997-05-26 | 2005-05-03 | 동아제약주식회사 | New preparation method of 2- [3-methoxy-4- (2,2,2-trifluoroethoxy) 2-pyridyl] methylsulfinyl-1H-benzimidazole |
| US6303787B1 (en) * | 1998-05-27 | 2001-10-16 | Natco Pharma Limited | Intermediates and an improved process for the preparation of Omeprazole employing the said intermediates |
| US6166213A (en) * | 1998-08-11 | 2000-12-26 | Merck & Co., Inc. | Omeprazole process and compositions thereof |
| US6191148B1 (en) | 1998-08-11 | 2001-02-20 | Merck & Co., Inc. | Omerazole process and compositions thereof |
| TWI289557B (en) | 1999-06-17 | 2007-11-11 | Takeda Chemical Industries Ltd | A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole |
| PL333847A1 (en) * | 1999-06-18 | 2001-01-02 | Inst Farmaceutyczny | Crystalline forms of lansoprozole and method of obtaining lansoprazole in pharmacologically advanthageous crystalline form |
| US6555139B2 (en) | 1999-06-28 | 2003-04-29 | Wockhardt Europe Limited | Preparation of micron-size pharmaceutical particles by microfluidization |
| US6245913B1 (en) | 1999-06-30 | 2001-06-12 | Wockhardt Europe Limited | Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole |
| AU5705700A (en) | 1999-06-30 | 2001-01-22 | Takeda Chemical Industries Ltd. | Crystals of benzimidazole compounds |
| US6316020B1 (en) | 1999-08-26 | 2001-11-13 | Robert R. Whittle | Pharmaceutical formulations |
| US6262086B1 (en) | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Pharmaceutical unit dosage form |
| US6312712B1 (en) | 1999-08-26 | 2001-11-06 | Robert R. Whittle | Method of improving bioavailability |
| US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| US6268385B1 (en) | 1999-08-26 | 2001-07-31 | Robert R. Whittle | Dry blend pharmaceutical formulations |
| US6262085B1 (en) | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| US6326384B1 (en) | 1999-08-26 | 2001-12-04 | Robert R. Whittle | Dry blend pharmaceutical unit dosage form |
| US6780880B1 (en) | 1999-08-26 | 2004-08-24 | Robert R. Whittle | FT-Raman spectroscopic measurement |
| US6312723B1 (en) | 1999-08-26 | 2001-11-06 | Robert R. Whittle | Pharmaceutical unit dosage form |
| KR100362947B1 (en) * | 1999-09-21 | 2002-11-30 | 주식회사 대웅 | Process for Preparing Sulfoxide Compound |
| DE19951960C2 (en) * | 1999-10-28 | 2002-06-27 | Gruenenthal Gmbh | Process for the preparation of benzimidazole derivatives suitable as ulcer therapeutics |
| EP1293507B1 (en) * | 2000-05-15 | 2007-11-28 | Takeda Pharmaceutical Company Limited | Process for producing crystal |
| KR20100002278A (en) | 2000-12-01 | 2010-01-06 | 다케다 야쿠힌 고교 가부시키가이샤 | Crystal of (r)- or (s)-lansoprazole |
| KR100430575B1 (en) * | 2001-02-21 | 2004-05-10 | 주식회사 씨트리 | Method of Preparing Lansoprazole and Its Intermediate |
| KR100783020B1 (en) * | 2001-03-23 | 2007-12-07 | 동아제약주식회사 | 2-Methylchloride Pyridine Derivative and Preparation Method of Benzimidazole Derivative Using the Same |
| US20040248941A1 (en) * | 2001-09-25 | 2004-12-09 | Keiji Kamiyama | Benzimidazone compound, process for producing the same, and use thereof |
| AU2003224779A1 (en) * | 2002-03-27 | 2003-10-13 | Teva Pharmaceutical Industries Ltd. | Lansoprazole polymorphs and processes for preparation thereof |
| KR100873419B1 (en) * | 2002-06-18 | 2008-12-11 | 페어차일드코리아반도체 주식회사 | Power semiconductor devices with high breakdown voltage, low on-resistance and small switching losses |
| EP1467987A1 (en) * | 2002-07-26 | 2004-10-20 | Teva Pharmaceutical Industries Ltd. | Preparation of lansoprazole and related compounds |
| ATE375338T1 (en) * | 2002-08-21 | 2007-10-15 | Teva Pharma | METHOD FOR THE PURIFICATION OF LANZOPRAZOLE |
| EP1764364A1 (en) * | 2002-08-21 | 2007-03-21 | Teva Pharmaceutical Industries Ltd | A method for the purification of lansoprazole |
| EP1552833B1 (en) * | 2002-10-16 | 2016-12-28 | Takeda Pharmaceutical Company Limited | Process for producing an amorphous optically active isomer of lansoprazole |
| EP1465890B1 (en) * | 2002-11-18 | 2007-04-04 | Teva Pharmaceutical Industries Ltd. | Stable lansoprazole containing more than 500 ppm, up to about 3,000 ppm water and more than 200 ppm, up to about 5,000 ppm alcohol |
| US7507829B2 (en) | 2002-12-19 | 2009-03-24 | Teva Pharmaceuticals Industries, Ltd | Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates |
| US7678816B2 (en) * | 2003-02-05 | 2010-03-16 | Teva Pharmaceutical Industries Ltd. | Method of stabilizing lansoprazole |
| EP1608649A2 (en) * | 2003-03-28 | 2005-12-28 | Sidem Pharma SA | Method for the enantioselective preparation of sulphoxide derivatives |
| FR2852956B1 (en) * | 2003-03-28 | 2006-08-04 | Negma Gild | PROCESS FOR THE ENANTIOSELECTIVE PREPARATION OF SULFOXIDE DERIVATIVES |
| MXPA05013316A (en) | 2003-06-10 | 2006-03-17 | Teva Pharma | Process for preparing 2-[(pyridinyl)methyl]sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole. |
| EP1768668A2 (en) | 2004-06-16 | 2007-04-04 | Tap Pharmaceutical Products, Inc. | Multiple ppi dosage form |
| EP1790647B1 (en) | 2004-09-13 | 2013-05-08 | Takeda Pharmaceutical Company Limited | Method for producing oxidized compound |
| EP1681056A1 (en) * | 2005-01-14 | 2006-07-19 | Krka Tovarna Zdravil, D.D., Novo Mesto | Process for preparing lansoprazole |
| KR100758600B1 (en) * | 2006-01-05 | 2007-09-13 | 주식회사 대웅제약 | Method for preparing lansoprazole crystalline form A |
| WO2008035189A1 (en) * | 2006-09-22 | 2008-03-27 | Orchid Chemicals & Pharmaceuticals Limited | A method for the purification of lansoprazole |
| WO2008092939A2 (en) | 2007-01-31 | 2008-08-07 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Process for the preparation of optically pure omeprazole via salt formation with a chiral amine or treatment with an entiomer converting enzyme and chromatographic separation |
| WO2009066309A2 (en) * | 2007-07-12 | 2009-05-28 | Cadila Healthcare Limited | Process for preparation of omeprazole |
| CN102014638A (en) | 2007-10-12 | 2011-04-13 | 武田制药北美公司 | Method of treating gastrointestinal disorders independent of food intake |
| AU2009224247B2 (en) | 2008-03-10 | 2013-12-12 | Takeda Pharmaceutical Company Limited | Crystal of benzimidazole compound |
| ES2343935B1 (en) * | 2008-12-29 | 2011-04-28 | Laboratorios Viñas S.A. | USEFUL INTERMEDIATES FOR OBTAINING 2- (2-PIRIDINILMETILSULFINIL) -1H-BENZIMIDAZOLES AND CORRESPONDING PROCEDURES. |
| KR20100101405A (en) * | 2009-03-09 | 2010-09-17 | 한미홀딩스 주식회사 | Method of preparing non-crystalline (+)-lansoprazole and (+)-lansoprazole alcoholate used therein |
| CN102180865B (en) * | 2011-03-17 | 2013-01-16 | 浙江工业大学 | Synthesis method of lansoprazole |
| US9119769B2 (en) | 2011-12-30 | 2015-09-01 | The Curators Of The University Of Missouri | Method for transforming pharmaceutical crystal forms |
| CN103724325B (en) * | 2013-12-10 | 2016-04-13 | 南京工业大学 | Process for preparing sulfinyl-1-hydro-benzimidazole derivatives |
| CN104019635B (en) * | 2014-06-19 | 2015-05-27 | 上海慈瑞医药科技有限公司 | Drying process for lansoprazole bulk drug |
| CN116891458A (en) * | 2023-06-19 | 2023-10-17 | 南京唯创远医药科技有限公司 | A kind of preparation method of ilaprazole |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE7804231L (en) * | 1978-04-14 | 1979-10-15 | Haessle Ab | Gastric acid secretion |
| US4472409A (en) * | 1981-11-05 | 1984-09-18 | Byk Gulden Lomberg Chemische Fabrik Gesellschaft Mit Beschrankter Haftung | 2-Pyridylmethyl thio(sulfinyl)benzimidazoles with gastric acid secretion inhibiting effects |
| HU195220B (en) * | 1983-05-03 | 1988-04-28 | Byk Gulden Lomberg Chem Fqb | Process for production of new fluor-alkoxi-benzimidasole-derivatives and medical compositions containig them |
| JPS6150979A (en) * | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | Pyridine derivative and preparation thereof |
| JPS6150978A (en) * | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | Pyridine derivative and preparation thereof |
| US4738975A (en) * | 1985-07-02 | 1988-04-19 | Takeda Chemical Industries, Ltd. | Pyridine derivatives, and use as anti-ulcer agents |
| DK171989B1 (en) * | 1987-08-04 | 1997-09-08 | Takeda Chemical Industries Ltd | Process for the preparation of 2- (2-pyridylmethylsulfinyl) benzimidazoles |
-
1988
- 1988-08-01 DK DK428188A patent/DK171989B1/en not_active IP Right Cessation
- 1988-08-03 IE IE237688A patent/IE61717B1/en not_active IP Right Cessation
- 1988-08-03 HU HU884076A patent/HU199828B/en unknown
- 1988-08-03 EP EP88307191A patent/EP0302720B1/en not_active Expired - Lifetime
- 1988-08-03 DE DE8888307191T patent/DE3875848T2/en not_active Revoked
- 1988-08-03 CA CA000573673A patent/CA1263119A/en not_active Expired
- 1988-08-03 AT AT88307191T patent/ATE82283T1/en active
- 1988-08-03 ES ES88307191T patent/ES2052728T3/en not_active Expired - Lifetime
- 1988-08-04 KR KR1019880009965A patent/KR960000047B1/en not_active Expired - Lifetime
-
1993
- 1993-02-04 GR GR930400224T patent/GR3006974T3/el unknown
-
1995
- 1995-04-27 US US08/430,178 patent/US5578732A/en not_active Expired - Lifetime
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995012590A1 (en) | 1993-11-04 | 1995-05-11 | Torcan Chemical Ltd. | Preparation of omeprazole and lansoprazole and intermediates useful therein |
| US6121454A (en) * | 1997-05-06 | 2000-09-19 | Pdi-Research Laboratories, Inc. | Synthesis of pharmaceutically useful pyridine derivatives |
| US6437139B1 (en) | 1997-05-06 | 2002-08-20 | Pdi-Research Laboratories, Inc. | Synthesis of pharmaceutically useful pyridine derivatives |
| US6077541A (en) * | 1997-11-14 | 2000-06-20 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
| US6096340A (en) * | 1997-11-14 | 2000-08-01 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
| US6780435B2 (en) | 1997-11-14 | 2004-08-24 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
| US6855336B2 (en) | 1998-08-28 | 2005-02-15 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
| US6174548B1 (en) | 1998-08-28 | 2001-01-16 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
| US6733778B1 (en) | 1999-08-27 | 2004-05-11 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
| US7129358B2 (en) | 2001-02-02 | 2006-10-31 | Teva Pharmaceutical Industries Ltd. | Processes for the production of substituted 2-(2-pyridylmethyl) sulfinyl-1H-benzimidazoles |
| EP1970374A1 (en) | 2001-02-02 | 2008-09-17 | Teva Pharmaceutical Industries Ltd. | Process for the production of substituted 2-(pyridin-2-ylmethylsulfinyl)-1H-benzimidazoles |
| WO2010134099A1 (en) | 2009-05-21 | 2010-11-25 | Cadila Healthcare Limited | One pot process for preparing omeprazole and related compounds |
| WO2013108068A1 (en) | 2012-01-21 | 2013-07-25 | Jubilant Life Sciences Limited | Process for the preparation of 2-pyridinylmethylsulfinyl benzimidazoles, their analogs and optically active enantiomers |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0302720A1 (en) | 1989-02-08 |
| DK428188D0 (en) | 1988-08-01 |
| IE882376L (en) | 1989-02-04 |
| US5578732A (en) | 1996-11-26 |
| HU199828B (en) | 1990-03-28 |
| DE3875848D1 (en) | 1992-12-17 |
| ES2052728T3 (en) | 1994-07-16 |
| KR890003738A (en) | 1989-04-17 |
| GR3006974T3 (en) | 1993-06-30 |
| EP0302720B1 (en) | 1992-11-11 |
| ATE82283T1 (en) | 1992-11-15 |
| DK428188A (en) | 1989-02-05 |
| KR960000047B1 (en) | 1996-01-03 |
| DE3875848T2 (en) | 1993-03-25 |
| DK171989B1 (en) | 1997-09-08 |
| HUT49346A (en) | 1989-09-28 |
| IE61717B1 (en) | 1994-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5578732A (en) | Production of 2-(2-pyridylmethylsulfinyl) benzimidazole compounds by selective oxidation in the presence of a vanadium catalyst | |
| KR101035534B1 (en) | Method of Making Crystal | |
| KR100242622B1 (en) | Proces for the preparation of anti-ulcer agents | |
| US6545024B1 (en) | Sulfoxide compounds and acetone complexes, and a process for producing the same | |
| RU2345075C2 (en) | Method of obtaining pharmaceutical remedies and compounds obtained by claimed method | |
| CA2402635C (en) | Method for oxidizing a thioether group into a sulfoxide group | |
| WO1982002042A1 (en) | Azetidine derivatives and process for their preparation | |
| MC1970A1 (en) | ACYL DERIVATIVES | |
| WO2008004245A1 (en) | Process for the preparation of optically pure or optically enriched enantiomers of sulphoxide compounds | |
| RU2237671C1 (en) | Method and ester derivatives used for preparing cephalosporins | |
| CA1275405C (en) | Penem derivatives | |
| KR101370844B1 (en) | Process for the preparation of pantoprazole sodium | |
| EP1476441B1 (en) | A method of eliminating sulfone analog in the synthesis of pyridine-benzimidazole sulfoxides | |
| EP0298177A1 (en) | Process for preparing pristinamycine IIB derivatives | |
| SU858565A3 (en) | Method of preparing 1,3-perhydrothiazine derivatives | |
| JPH0686444B2 (en) | Process for producing 2- (2-pyridylmethylsulfinyl) benzimidazole compound | |
| KR100869677B1 (en) | Method of Making Crystal | |
| KR960011778B1 (en) | Novel process for preparing crystalline hydrate of cephalosporin | |
| KR100464174B1 (en) | A process for preparation of sulfinyl benzimidazole derivatives | |
| HU195222B (en) | Process for production of pename-, cefem- and cefamsulphons | |
| CZ286105B6 (en) | Process for preparing 2-azetidinones and intermediate for preparation thereof | |
| KR20020068140A (en) | Method for Preparing [(2-Oxo-3-tetrahydrothienylcarbamoyl)-methyl thio] acetic acid | |
| BE821163A (en) | PENAM DERIVATIVES AND THEIR PREPARATION | |
| HK40011933A (en) | Method for preparing intermediate of 4-methoxypyrrole derivative | |
| EP0120094A1 (en) | Azetidinone compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |